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ABSTRACT The available treatments for leishmaniasis are less than optimal due to
inadequate efﬁcacy, toxic side effects, and the emergence of resistant strains, clearly
endorsing the urgent need for discovery and development of novel drug candidates.
Ideally, these should act via an alternative mechanism of action to avoid cross-
resistance with the current drugs. As cyclic nucleotide-speciﬁc phosphodiesterases
(PDEs) of Leishmania major have been postulated as putative drug targets, a series
of potential inhibitors of Leishmania PDEs were explored. Several displayed potent
and selective in vitro activity against L. infantum intracellular amastigotes. One imi-
dazole derivative, compound 35, was shown to reduce the parasite loads in vivo and
to increase the cellular cyclic AMP (cAMP) level at in a dose-dependent manner at
just 2 and 5 the 50% inhibitory concentration (IC50), indicating a correlation be-
tween antileishmanial activity and increased cellular cAMP levels. Docking studies
and molecular dynamics simulations pointed to imidazole 35 exerting its activity
through PDE inhibition. This study establishes for the ﬁrst time that inhibition of
cAMP PDEs can potentially be exploited for new antileishmanial chemotherapy.
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The term “leishmaniasis” represents a group of diseases caused by trypanosomatidprotozoans that belong to the genus Leishmania; more than 20 species in the genus
are responsible for these poverty-associated diseases. The clinical outcomes can be
grouped into two main forms of the disease: (i) visceral leishmaniasis (VL) caused by
Leishmania donovani and L. infantum and (ii) cutaneous leishmaniasis (CL) caused by L.
major, L. tropica, and L. mexicana, among other species. VL is fatal if left untreated,
affecting vital organs such as liver, spleen, and bone marrow. In contrast, CL causes the
formation of ulcers that may heal spontaneously but leave permanent, disﬁguring scars
(1, 2). Leishmaniasis is a major health problem in tropical and subtropical countries
where the sand ﬂy vector is abundantly present. Although the disease has its main
impact in developing countries of Southeast Asia, East Africa, and Latin America, it is
also endemic around the Mediterranean Sea (3). The rapid increase in cases of coin-
fection with HIV, facilitated by the impact of Leishmania on the immune system, is an
increasing concern (4).
Despite ongoing efforts toward antileishmanial immunotherapy, a promising hu-
man vaccine has not yet been developed (5). This fact, together with the challenges in
controlling the sandﬂy vectors (6), ensures that management of this neglected disease
continues to rely almost exclusively on chemotherapy. Current treatments include
pentavalent antimonials, liposomal amphotericin B, pentamidine, paromomycin, and
miltefosine. However, these drugs all have severe drawbacks relating to toxicity,
stability, cost, and/or the spread of drug-resistant strains. With the exception of
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miltefosine, all require parenteral administration (7). Alternatives to the current drugs
are therefore urgently needed. Ideally, drugs with a novel mechanism of action that are
able to overcome resistance to the current drugs and to be delivered by oral admin-
istration are desirable (8–10).
Inhibitors of parasite enzymes that are homologous to human enzymes with a
well-studied pharmacology may be a good starting point to look for new drugs; as
such, target repurposing immediately unlocks a toolbox of potential inhibitors, enzyme
structure assays, and assorted other forms of pharmacological and pharmaceutical
know-how. With this in mind, human phosphodiesterases (PDEs) are well-studied
enzymes essential for cyclic nucleotide signaling, whose druggability has been ex-
ploited in various human pathologies, leading to the production of several marketed
drugs (11). Speciﬁc targeting of parasite PDEs could provide interesting options for the
development of PDE inhibitors as antiprotozoal drugs (12, 13). PDEs are responsible for
the hydrolysis of cyclic nucleotides, but their signaling role in trypanosomatids is not
yet fully understood (14, 15). Since cyclic AMP (cAMP) is clearly involved in the
pathogenesis (16), agents able to increase cAMP levels in the parasite, such as PDE
inhibitors, may have therapeutic potential (17). Indeed, inhibition of PDEs was shown
to lead to runaway cellular cAMP levels and cell death in several protozoan parasites
(18–20), but this has yet not been investigated in Leishmania.
The L. major genome encodes ﬁve class I PDEs: L. major PDEA (LmjPDEA), LmjPDEB1,
LmjPDEB2, LmjPDEC, and LmjPDED (21). LmjPDEA, LmjPDEB1, and LmjPDEB2 were shown
to complement a cAMP-PDE-deﬁcient yeast strain, with LmjPDEB1 and LmjPDEB2 being
cAMP speciﬁc and the activity of LmjPDEA being lower and not fully characterized (22),
although its overexpression in L. donovani decreased promastigote infectivity with respect
to macrophages and impacted resistance to oxidative stress (23). The commercial PDE
inhibitors dipyridamole, trequinsin, and etazolate were shown to inhibit LmjPDEB1 and
LmjPDEB2 and the proliferation of L. major promastigotes in vitro; however, due to the high
inhibitor concentrations needed for these effects and the omission of a direct demonstra-
tion of any perturbation of the cellular cAMP concentration (22), ultimate validation of
Leishmania PDEs as drug targets is still lacking.
Meanwhile, the X-ray structure of LmjPDEB1 showed a high level of similarity with
that of the catalytic site of human PDEs but also revealed a parasite-speciﬁc subpocket
(p-pocket) near the active site, which could enable the design of parasite-selective
inhibitors (24). This area is not accessible to inhibitors in the human PDEs due to a lower
volume and changes in the entry residues, which isolate it from the catalytic site. For
this reason, this p-pocket would be very useful for the design of selective inhibitors. In
L. major PDEB1, this domain is formed by residues Met874 to Gly886, which act as its
gating residues.
TABLE 1 In vitro antiparasitic activities of quinazoline-like hPDE7A inhibitorsa
Comp. X R1 R2 R3
(IC50 [M])
hPDE7A (25) MRC-5 T. cruzi L. infantum T. brucei PMM
1 S H H H 0.6 64.0 51.5 64.0 60.6 64.0
2 S H Me 2-Br 5.3 3.2 5.0 64.0 33.4
3 O 6-Br H 2,6-diF 11.0 64.0 64.0 64.0 64.0
4 O H H H 4.7 64.0 64.0 64.0 37.4 64.0
5 O H Me 2,6-diF 4.7 29.3 64.0 64.0 51.7 64.0
6 O 8-Me H 2-Br 2.0 64.0 64.0 64.0 64.0 64.0
7 O 6-Br Me 2-Br 0.7 6.7 8.6 26.4 19.4 32.0
aIC50 data represent inhibition of the growth of T. cruzi, L. infantum, and T. brucei or cytotoxicity toward human lung ﬁbroblasts (MRC-5 cells) and primary peritoneal
mouse macrophages (PMM). Each value represents the mean of data from two independent determinations. Comp., compound; hPDE7A, human PDE7A.
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The present report presents selected human PDE inhibitors as pharmacological tools
to validate the Leishmania PDEs as potential drug targets.
RESULTS
In vitro activity. A small focused library with 30 chemically diverse human cAMP
PDE inhibitors, speciﬁcally, inhibitors of PDE7A and PDE10A, designed and synthesized
in our laboratory was evaluated phenotypically against a panel of three pathogenic
trypanosomatids: Trypanosoma brucei, T. cruzi, and L. infantum. Cytotoxicity evaluation
was carried out on human lung ﬁbroblasts (MRC-5) and primary peritoneal mouse
macrophages (PMM). A ﬁrst selection included heterocyclic compounds with molecular
weights (MW) of 500 Da and different scaffolds, such as quinazolines (Table 1) (25),
furans (Table 2) (26), iminothiadiazoles (Table 3) (27), sulﬁdes (Table 4) (28), and
imidazoles (Table 5) (29). Only the imidazole compounds showed some inhibitory
potential, and to check whether this core could be regarded as a privileged scaffold, 62
imidazole-related compounds from our Medicinal and Biological Chemistry (MBC)
library (30) were evaluated next (Table 6). Four hits (compounds 35, 45, 66, and 78) were
nontoxic to MRC-5 (50% cytotoxic concentration [CC50], 64 M), with potent activity
against intracellular amastigotes of L. infantum and/or T. cruzi (Fig. 1). Compounds 66
and 78 showed a 50% inhibitory concentration (IC50) in the same range as that of
TABLE 2 In vitro antiparasitic activities of furan-like hPDE7A inhibitorsa
Comp. R1 R2
(IC50 [M])
hPDE7A (26) MRC-5 T. cruzi L. infantum T. brucei PMM
8 Me H 5.2 64.0 64.0 64.0 64.0 64.0
9 Me 4-Cl,2-NO2 7.3 35.5 33.0 64.0 34.0
10 Me 2,4-diCl 10b 64.0 64.0 64.0 57.4 64.0
11 Me 4-Me 10c 28.6 64.0 64.0 62.9 64.0
12 Et H 10c 64.0 24.5 33.2 30.3 64.0
aIC50 data represent inhibition of the growth of T. cruzi, L. infantum, and T. brucei or cytotoxicity toward human lung ﬁbroblasts (MRC-5 cells) and primary peritoneal
mouse macrophages (PMM). Each value represents the mean of data from two independent determinations.
b38% inhibition at 10 M.
c30% inhibition at 10 M.
TABLE 3 In vitro antiparasitic activities of iminothiadiazole-like hPDE7A inhibitorsa
Comp. R1 X
(IC50 [M])
hPDE7A (27) MRC-5 T. cruzi L. infantum T. brucei PMM
13 -CH2CH2-OH Br 1.1 29.3 48.2 32.5 64.0 32.0
14 -(CH2)2-Morph 2Br 1.6 30.3 48.3 32.5 60.0 32.0
15 -CH2-3Pyr 2Br 0.4 7.5 8.1 26.4 35.7 32.0
16 H Br 1.0 30.1 32.3 32.5 39.2 32.0
aIC50 data represent inhibition of the growth of T. cruzi, L. infantum, and T. brucei or cytotoxicity toward human lung ﬁbroblasts (MRC-5 cells) and primary peritoneal
mouse macrophages (PMM). Each value represents the mean of data from two independent determinations.
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benznidazole (IC50  3.18 M) (31) against T. cruzi, while compounds 45 and 35 tested
against L. infantum showed IC50s below that of miltefosine (IC50  7.56 M) (31).
In vitro metabolic stability. The selected imidazoles were exposed to mouse S9
microsomal fractions to investigate the in vitro metabolic stability through phase I
metabolism and phase II metabolism (Table 7). The T. cruzi hits corresponding to
compounds 66 and 78 were both extensively metabolized through phase I metabolism
with, respectively, 5% and 24% of parent drug remaining after 15 min. Phase II
metabolism was lower, with 82% and 66% remaining after 15 min and about 50% after
60 min. For the L. infantum hits corresponding to compounds 45 and 35, no extensive
phase I or phase II metabolism could be demonstrated, indicating satisfactory meta-
bolic stability and suitability for in vivo follow-up evaluation. The reference drug
diclofenac showed extensive phase I and phase II metabolism, conﬁrming proper
functioning of the assay.
Computational studies. To study the binding mode of imidazole compounds 35
and 45 in the LmjPDEB1 catalytic site, docking studies were performed as a starting
point for dynamic simulations and were centered on a key residue of the catalytic site,
Gln887. For both compounds, the best conformation binds the catalytic site of the
enzyme, making key interactions with residues Gln887, Phe857, and Phe890 that allow
the formation of a stable protein-ligand complex. In both complexes, the compounds
TABLE 4 In vitro antiparasitic activities of sulﬁde-like hPDE7A inhibitorsa
Comp. Form R1 R3 R4 R1= R3=
(IC50 [M])
hPDE7A (28) MRC-5 T. cruzi L. infantum T. brucei PMM
17 A NO2 Cl H H NH2 0.4 64.0 64.0 64.0 48.0 64.0
18 B NO2 Cl H 0.7 64.0 27.2 12.7 19.1
19 A NO2 Cl H Br H 1.0 64.0 28.8 38.0 32.0
20 A NO2 H Cl NHAc H 2.1 64.0 50.9 64.0 64.0 64.0
21 A Cl NO2 H NH2 H 8.8 35.3 29.0 64.0 32.6 64.0
22 A NO2 H Cl Br H 1.0 16.9 22.9 51.0 32.9 64.0
23 B Cl NO2 H 0.2 64.0 36.7 64.0 47.3 64.0
aIC50 data represent inhibition of the growth of T. cruzi, L. infantum, and T. brucei or cytotoxicity toward human lung ﬁbroblasts (MRC-5 cells) and primary peritoneal
mouse macrophages (PMM). Each value represents the mean of data from two independent determinations.
TABLE 5 In vitro antiparasitic activities of imidazole-like hPDE10A inhibitorsa
Comp. R1 R2 R3 R4
(IC50 [M])
hPDE10A (29) MRC-5 T. cruzi L. infantum T. brucei PMM
24 3,4-diCF3-Ph 4-OMe-Ph H H 0.4 15.4 6.1 32.2 2.0
25 2-Cl-Ph 4-Br-Ph 4-Br-Ph H 0.02 64.0 2.2 50.8 2.2
26 4-Cl-Ph 4-OMe-Ph H H 2.0 19.8 17.8 26.4 29.6 32.0
27 H 4-Br-Ph 4-Br-Ph H 0.2 42.5 64.0 32.5 64.0 32.0
28 2-Br-Ph 4-Br-Ph 4-Br-Ph H 0.4 64.0 18.0 64.0 8.2 64.0
29 Ph Ph Ph Me 4.1 50.6 8.2 20.6 20.2 64.0
30 2-Br-Ph 4-OMe-Ph 4-OMe-Ph H 2.2 64.0 7.3 14.3 7.5 32.0
aIC50 data represent inhibition of the growth of T. cruzi, L. infantum, and T. brucei or cytotoxicity toward human lung ﬁbroblasts (MRC-5 cells) and primary peritoneal
mouse macrophages (PMM). Each value represents the mean of data from two independent determinations.
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TABLE 6 In vitro antiparasitic activities of imidazole derivatives from the MBC librarya
Comp. R1 R2 R3 R4
(IC50 [M])
MRC-5 T. cruzi L. infantum T. brucei PMM
31 2-OMe-Ph 4-Br-Ph 4-Br-Ph H 64.0 64.0 48.2 64.0 48.0
32 3-Cl-Ph 4-Br-Ph 4-Br-Ph H 45.8 64.0 7.5 2.0 8.0
33 4-Cl-Ph 4-Br-Ph 4-Br-Ph H 64.0 64.0 20.3 64.0 20.0
34 Ph 4-Br-Ph 4-Br-Ph H 64.0 64.0 48.2 64.0 48.0
35 2,4-diOMe-Ph 4-Br-Ph 4-Br-Ph H 64.0 7.6 5.2 11.7 64.0
36 2,5-diOMe-Ph 4-Br-Ph 4-Br-Ph H 64.0 17.8 15.0 14.1 64.0
37 2-OMe-Ph 4-Br-Ph 4-Br-Ph Bn 64.0 6.8 6.7 8.1 48.0
38 2-Cl-Ph 4-Br-Ph 4-Br-Ph Bn 64.0 14.2 9.4 8.1 36.0
39 2,4-diOMe-Ph 4-Br-Ph 4-Br-Ph Me 36.4 51.3 18.8 8.2 32.0
40 2,5-diOMe-Ph 4-Br-Ph 4-Br-Ph Et 64.0 18.7 16.5 32.5 48.0
41 2-Cl-Ph 4-OMe-Ph 4-OMe-Ph H 64.0 7.9 16.5 7.0 32.0
42 2-OMe-Ph 4-OMe-Ph 4-OMe-Ph H 64.0 64.0 48.2 64.0 48.0
43 Ph 4-OMe-Ph 4-OMe-Ph H 6.3 8.1 5.9 6.6 48.0
44 2-OMe-Ph 4-OMe-Ph 4-OMe-Ph Bn 64.0 4.6 6.7 7.8 36.0
45 2-Cl-Ph 4-OMe-Ph 4-OMe-Ph Bn 64.0 5.1 5.1 8.1 48.0
46 Ph Ph Ph H 52.5 64.0 64.0 64.0 64.0
47 Ph Ph Ph Et 31.2 47.4 42.1 48.3 64.0
48 Ph Ph H H 55.1 47.9 64.0 64.0 64.0
49 2,4,5-triOMe-Ph Ph H H 19.3 39.2 29.8 25.3 32.0
50 2,4-diOMe-Ph Ph H H 16.6 49.4 35.2 31.0 48.0
51 2,5-diOMe-Ph Ph H H 28.9 33.3 48.2 27.6 48.0
52 2-OMe-Ph Ph H H 30.7 50.6 32.8 58.9 48.0
53 3-Me-Ph Ph H H 30.4 29.5 20.3 27.3 32.0
54 4-F-Ph Ph H H 21.9 48.3 32.5 25.6 32.0
55 4-Me-Ph Ph H H 10.6 28.8 29.9 25.0 32.0
56 2-Cl-Ph Ph H H 37.2 49.1 48.2 64.0 48.0
57 3-Me-Ph Ph H Bn 64.0 20.3 26.7 29. 6 64.0
58 4-Me-Ph Ph H Bn 49.3 7.0 20.4 8.2 32.0
59 2,4,5-triOMe-Ph Ph H Bn 29.0 18.6 12.0 32.5 48.0
60 2-Cl-Ph Ph H Bn 28.5 7.8 53.53 8.345 64.0
61 Ph 2-naphtyl H H 35.7 54.9 36.05 64.0 36.0
62 Ph 4-OMe-Ph H H 13.9 31.8 48.23 37.5 48.0
63 4-OMe-Ph H H 4.9 11.5 20.28 25.0 20.0
64 4-Br-Ph H H 7.2 7.9 20.28 8.075 20.0
65 Ph 4-Br-Ph H H 5.5 8.5 48.2 26.5 48.0
66 2-Pyr 4-Br-Ph H H 64.0 4.7 14.6 14.8 48.0
67 3,5-diCF3-Ph 4-Br-Ph H H 3.5 5.5 2.0 2.00 5.0
68 4-Cl-Ph 4-Cl-Ph H H 10.1 8.7 20.3 9.4 32.0
69 4-Cl-Ph 4-Cl-Ph H Bn 64.0 9.1 20.3 9.8 48.0
70 Ph 4-Cl-Ph H Bn 61.6 7.7 16.51 8.1 32.0
71 3,5-diCF3-Ph 3-Pyr H H 64.0 64.0 48.2 2.0 48.0
72 H 4-OMe-Ph 4-OMe-Ph H 5.9 46.3 64.0 64.0 64.0
73 H Me Ph H 64.0 64.0 64.0 64.0 64.0
74 H Ph Ph H 64.0 64.0 64.0 64.0 64.0
75 H Ph Ph Me 64.0 48.7 35.6 64.0 48.0
76 H Ph Ph Et 25.8 46.5 32.5 64.0 32.0
77 H Ph Ph Bu 32.3 22.9 23.7 32.4 48.0
78 H Ph Ph CH2-4-Cl-Ph 64.0 4.5 48.0 8.1 64.0
79 H Ph Ph CH2-4-CF3-Ph 64.0 15.7 42.2 9.0 48.0
80 H Ph Ph CH2-2-Cl-Ph 14.1 18.2 64.0 26.9 64.0
(Continued on next page)
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appear to be able to target the parasite-speciﬁc pocket, as the docking studies showed
the methoxyphenyl substituent of either compound entering the p-pocket (Fig. 2). The
best-ranked conformation of compound 35 was selected as the starting point for the
molecular dynamics (MD) studies. The results revealed stability of the complex, and to
analyze the binding mode in detail, the interactions were monitored during the
simulation time of 20 ns. Most of the key interactions found in the docking pose were
maintained throughout the run time, conﬁrming that the hydrogen bond with Gln887
and the aromatic interactions with Phe857 and Phe890 provide the stability of the
complex. Through this simulation process, it was also possible to identify some inter-
actions with hydrophobic residues from the hydrophobic clamp. Importantly, the
methoxy group was able to make a hydrogen bond with a residue inside the p-pocket,
Asn881, as early as ns 5 of the simulation, and this interaction was stably maintained
during the rest of the simulation process (see Fig. S1 in the supplemental material).
Efﬁcacy in the L. infantum BALB/c mouse model. On the basis of the metabolic
stability data and their possible interaction with Leishmania PDEB1, derivatives 35 and
45 were selected for a proof-of-concept in vivo assessment. Both were administered
orally in the L. infantum BALB/c mouse model at 50 mg/kg of body weight (BW) twice
a day (b.i.d.) for 5 days. Amastigote burdens in the liver and spleen target organs were
determined on days 16 and 17 of the experiment (Table 8). The results are expressed
as Leishman Donovan units (LDU; mean numbers of amastigotes per liver/spleen cell
TABLE 6 (Continued)
Comp. R1 R2 R3 R4
(IC50 [M])
MRC-5 T. cruzi L. infantum T. brucei PMM
81 H Ph Ph Bn 12.2 19.6 38.3 23.2 64.0
82 H Ph Ph CH2-biPh 6.7 7.9 36.0 20.7 36.0
83 H Ph Ph CH2-4-Pyr 44.4 47.4 48.2 32.7 48.0
84 H Ph Ph CH2-3-Cl-Ph 8.0 20.4 42.2 8.2 48.0
85 H Ph Ph CH2-4-SMe-Ph 64.0 64.0 64.0 64.0 64.0
86 H Ph Ph CO-Ph 64.0 64.0 48.2 64.0 48.0
87 H Ph Ph CH2-3,4-diCF3-Ph 6.2 5.0 8.6 8.0 20.0
88 H 4-Br-Ph H H 64.0 47.0 64.0 64.0 64.0
89 H 4-Br-Ph H Bn 64.0 47.8 49.3 32.6 64.0
90 H 4-Br-Ph H CH2-3,4-diCF3-Ph 64.0 64.0 64.0 8.7 64.0
91 H Ph H Bn 48.8 48.7 48.2 58.4 48.0
92 H 4-F-Ph H Bn 20.0 48.2 45.6 32.3 48.0
aIC50 data represent inhibition of the growth of T. cruzi, L. infantum, and T. brucei or cytotoxicity toward human lung ﬁbroblasts (MRC-5 cells) and primary peritoneal
mouse macrophages (PMM). Each value represents the mean of data from two independent determinations.
FIG 1 Selected imidazole hits for further studies. Comp, compound.
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per milligram of liver/spleen). The vehicle-treated controls showed high amastigote
burdens in the liver (LDU  618  30) and lower burdens in the spleen (LDU  16 
3) since the infection is primarily established in the liver around day 14 postinfection.
Oral miltefosine (40 mg/kg once a day [s.i.d.] for 5 days) displayed excellent activity,
with parasite burdens in liver and spleen reduced by 98.9% and 96.1%. Upon oral
dosing at 50 mg/kg b.i.d. for 5 days, parasite burdens in liver and spleen were reduced
by 32.4% and 38.9% for compound 45 and by 36.4% and 57.0% for compound 35.
In vitro cAMP measurements in Leishmania promastigotes. To establish whether
imidazole 35 induces an increase in intracellular cAMP levels in L. infantum promasti-
gotes, the cAMP response was tested at concentrations corresponding to 2 and 5
its IC50 against intracellular amastigotes. The experiment was performed on promasti-
gotes since it is not possible to measure cAMP levels for intracellular amastigotes, with
their cAMP content masked by that of the host cells, or to obtain sufﬁcient numbers of
amastigotes from the infected animals without some host cell contamination. The
chosen concentrations had no effect on promastigote viability over the 3 h of the
experiment. The compound induced a signiﬁcant and dose-dependent increase in
cellular cAMP levels in the promastigotes (Fig. 3), consistent with inhibition of one or
more PDEs in the same concentration range as its antileishmanial effects. The tetrahy-
drophthalazinone NPD0001, a potent inhibitor of T. brucei PDEB1 (TbrPDEB1) and
TbrPDEB2 (18, 32), was used as a positive control for a strong cAMP response.
DISCUSSION
One major health problem in tropical and subtropical countries is leishmaniasis,
which is also endemic in the Mediterranean area. Although effective drugs exist for
TABLE 7 In vitro metabolic stability: percentage of parent compounds over time in the presence of mouse liver microsomes
Phase I/II
Time
(min)
% parent compound remaining upon incubation
Comp. 35
(n  3)
Comp. 45
(n  3)
Comp. 66
(n  3)
Comp. 78
(n  3)
Diclofenac
(n  3)
Avg SD Avg SD Avg SD Avg SD Avg SD
CYP450-NADPH (phase
I metabolism)
0 100 100 100 100 100
15 103 3.6 128 24.6 5 0.8 24 11.5 83 22.7
30 100 0.5 109 25.8 2 0.2 4 2.8 68 20.5
60 81 2.0 168 79.5 2 0.2 2 1.5 61 20.4
UGT enzymes (phase II
metabolism)
0 100 100 100 100 100
15 102 9.4 90 9.2 82 3.0 66 20.8 35 5.9
30 99 9.4 76 25.6 64 9.3 59 26.9 38 2.1
60 104 10.8 62 19.3 53 9.9 50 28.7 51 27.8
FIG 2 Docking results for imidazole compounds 35 (cyan) and 45 (yellow) in LmjPDEB1. A global view of
the protein and a zoomed view of the catalytic binding site, key residues, and the p-pocket (in a gray
circle) are shown.
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therapy, the side effects and the spread of drug-resistant strains make the discovery of
novel drugs with a new mechanism of action urgent. It is increasingly argued that the
search of new leishmanicidal agents should be based on well-known targets with
established pharmacology, as such target repurposing greatly speeds up the drug
discovery process; the cAMP PDEs fall into that category. The similarity between the
human and protozoan enzymes, together with the availability of human PDE inhibitors
as reputable therapeutics, paved the way for the development of speciﬁc inhibitors of
protozoan PDEs as potential drugs (33).
On the basis of this reasoning and of the powerful results obtained by the repurposing
of human drugs for antitrypanosomatid therapy (34), 30 known inhibitors of human PDEs
from our in-house library were initially selected and tested in a primary in vitro screening
against a broad panel of pathogens and mammalian cell lines (Tables 1 to 5). Within our
experience in the design and development of speciﬁc cAMP-hPDE inhibitors, this study
speciﬁcally aimed at the identiﬁcation of novel scaffolds for inhibition of protozoan PDEs.
The ﬁnding that imidazoles with multiple phenyl substitutions showed a tendency to
inhibit trypanosomatid growth triggered a subsequent screen of a larger focused library
composed of 62 structurally related imidazoles (Table 6) and produced four hits (com-
pounds 35, 45, 66, and 78). These compounds showed promising in vitro activity against L.
TABLE 8 In vivo activity of imidazoles 45 and 35 in the L. infantum BALB/c mouse model with respect to organ burden and percentage
of efﬁcacy
Dosing group
Amastigote burden
Liver Spleen
Mean  SD LDU % reduction Mean SD LDU % reduction
G1 (vehicle [PEG 400]) 618 30 16 3
G2 (miltefosine at 40 mg/kg s.i.d. p.o.a for 5 days) 7 2 98.9 1 0 96.1
G3 (Comp. 45 at 50 mg/kg b.i.d. p.o. for 5 days) 418 56 32.4 10 2 38.9
G4 (Comp. 35 at 50 mg/kg b.i.d. p.o. for 5 days) 393 28 36.4 7 1 57.0
ap.o., orally.
FIG 3 Intracellular cAMP in L. infantum promastigotes after 3 h of incubation. Imidazole 35 was used at
2 and at 5 the IC50 concentration of 5.1 M.
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infantum or T. cruzi intracellular amastigotes, with adequate selectivity with respect to
cytotoxicity in MRC-5 cells (selectivity index [SI], 12) (Fig. 1).
The metabolic stability of compounds in early drug development is one of the
drug-like properties used in candidate prioritization for progression (35) and directly
supports in vivo follow-up experiments. To evaluate their suitability for in vivo evalua-
tion, the in vitro metabolic stability of the hit compounds was assessed using mouse S9
microsomal fraction, with the results showing acceptable stability for both compound
35 and compound 45 (Table 7).
To investigate whether the selected compounds are able to bind the PDE
catalytic site, molecular modeling approaches were employed using the published
LmjPDEB1 crystal structure (2R8Q) (24). Note that the L. major and L. infantum PDEB1s
are almost identical, displaying identity levels of 95.7% between the full-length open
reading frames and 97.4% for the catalytic domains (see Fig. S2 in the supplemental
material).
Docking calculations followed by molecular dynamics simulations evidenced
that these imidazole compounds are able to bind the active site of Leishmania major
PDEB1. In addition to interactions with the expected conserved residues, such as
the hydrogen bond with Gln887 and the aromatic interactions with Phe857 and
Phe890, both compounds were able to target the parasite-speciﬁc pocket through
a bond between their methoxyphenyl substituent and residue Asn881. This inter-
action with the p-pocket is crucial for speciﬁcity with respect to human PDEs and
was maintained during a molecular dynamics simulation (Fig. 2), opening new
avenues for the speciﬁc design of PDE parasitic inhibitors. To conﬁrm that the effect
of the compounds was indeed the result of PDE inhibition in the parasite, a
measurable increase in cellular cAMP levels should occur. Consistent with this
expectation, imidazole 35 induced a signiﬁcant dose-dependent increase in the
intracellular cAMP content of L. infantum promastigotes at concentrations just
above the antileishmanial IC50, reaching a level similar to that seen with the potent
reference inhibitor NPD0001 (Fig. 3).
Metabolically stable imidazoles were advanced to the L. infantum-infected mouse
model. Oral treatment of 50 mg/kg of body weight b.i.d. for 5 days with compound 35 or
45 resulted in a 30% to 60% reduction in the parasite burden, which represents only
moderate in vivo activity compared to that of miltefosine (Table 8). Yet these results
encourage further efforts toward optimization of the hit compounds by structure-aided
medicinal chemistry, in order to improve drug-like properties such as oral bioavailability.
In conclusion, this is the ﬁrst time that a PDE inhibitor with a conﬁrmed correlation
between in vitro antileishmanial activity and cAMP content was shown to exhibit in vivo
activity, which constitutes an important step toward establishing Leishmania PDEs as
drug targets. On the basis of these results, imidazole derivatives can be regarded as
promising hits to be developed in a hit-to-lead program to obtain new drug candidates
for leishmaniasis with a better and safer pharmaceutical proﬁle.
MATERIALS AND METHODS
Ethics statement. The use of laboratory rodents was carried out in strict accordance to all mandatory
guidelines (EU directives, including the Revised Directive 2010/63/EU on the Protection of Animals used
for Scientiﬁc Purposes that came into force on 1 January 2013 and the declaration of Helsinki in its latest
version) and was approved by the ethical committee of the University of Antwerp, Belgium [UA-ECD
2016-54 (02/09/2016)].
Compounds studied. All the compounds tested in this work had a purity level of 95% by
high-performance liquid chromatography (HPLC) and are collected in the MBC library (30). The following
compounds were prepared in the Centro de Investigaciones Biológicas (CIB-CSIC) using procedures
described previously in the indicated references: quinazolines (compounds 1 to 7) (25), furans (com-
pounds 8 to 12) (26), iminothiadiazoles (compounds 13 to 16) (36), sulﬁdes (compounds 17 to 23) (28),
and imidazoles (compounds 24 to 92) (29).
In vitro parasite growth inhibition assays. Integrated screening was used to deﬁne the activity
proﬁles of the test compounds (compounds 1 to 92), adopting standard assay protocols as previously
described (37). A brief description of each model is given. (i) Leishmania amastigotes harvested from the
spleen of infected donor hamsters were used for infection. Murine peritoneal macrophages were
obtained after intraperitoneal stimulation with 2% starch–water for 24 to 48 h and plated in 96-well
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microplates at 104 cells/well. After 105 amastigotes were added per well and after 5 days of incubation,
parasite burdens were microscopically assessed after Giemsa staining. (ii) African trypanosome blood-
stream forms of a drug-sensitive T. brucei strain were axenically grown in Hirumi-9 medium at 37°C under
an atmosphere of 5% CO2. Assays are performed in 96-well tissue culture plates, with each well
containing 104 parasites. After 4 days of incubation, parasite growth was assessed by adding resazurin
and ﬂuorimetric reading after 4 h at 37°C. (iii) For a Chagas disease-related model, a nifurtimox-sensitive
Tulahuen strain (LacZ transfected) of T. cruzi was maintained on MRC-5 cells. Assays were performed in
96-well tissue culture plates, with each well containing the compound dilutions together with 3  103
MRC-5 cells and 3 104 trypomastigotes. After 7 days of incubation, colorimetric reading was performed
after addition of chlorophenol red beta-D-galactopyranoside as the substrate. (iv) For a cytotoxicity
model, MRC-5 cells were cultured in minimal essential medium (MEM) supplemented with 20 mM
L-glutamine, 16.5 mM NaHCO3, and 5% fetal calf serum. Assays are performed at 37°C and 5% CO2 in
96-well tissue culture plates with conﬂuent monolayers. After 7 days of incubation, cell proliferation and
viability were assessed after addition of resazurin and ﬂuorescence reading.
Microsomal stability assays.Mouse liver microsomes (S9), NADPH-generating system solutions, and
uridine glucuronosyl transferase (UGT) reaction mix (BD Biosciences) were kept at 80°C. The test
compounds (compounds 35, 45, 66, and 78), the internal standard tolbutamide, and the reference
compound diclofenac were formulated in dimethyl sulfoxide (DMSO) at 10 mM. The assay was carried out
based on the BD Biosciences guidelines for use (TF000017 Rev1.0) with minor adaptations. The metabolic
stability of the compounds was studied through the use of members of the CYP450 superfamily (phase
I metabolism) by fortiﬁcation with NADPH and through the use of uridine glucuronosyl transferase (UGT)
enzymes (phase II metabolism) by fortiﬁcation with UDP glucuronic acid (UDPGA). For CYP450 and other
NADPH-dependent enzymes, the compounds were incubated at 5 M together with 0.5 mg/ml S9–
potassium phosphate buffer in a reaction started by the addition of 1 mM NADP. At deﬁned time points,
20 l was withdrawn from the reaction mixture and 80 l cold acetonitrile (ACN) was added to inactivate
the enzymes and precipitate the protein. The mixture was subjected to vortex mixing for 30 s and
centrifuged at 4°C for 5 min to collect the supernatant. For UGT enzymes, the compounds were
incubated at 5 M together with 0.5 mg/ml S9 in a reaction started by the addition of 2 mM UDPGA
cofactor. The loss of the parent compound was determined using ultraperformance liquid chromatog-
raphy (UPLC) and a Waters Acquity system coupled with tandem quadrupole mass spectrometry (MS2)
(Waters Xevo), equipped with an electrospray ionization (ESI) interface, and operated in multiple-
reaction-monitoring (MRM) mode.
Docking studies. Compounds 35 and 45 were prepared and converted into three-dimensional (3D)
data for computational studies using the Ligprep tool (38), a module of the Schrödinger software
package. All possible states at the target pH of 7.0  1 were generated, and stereoisomers and
low-energy ring conformations were allowed during the process. The crystal structure (24) of LmjPDEB1
was retrieved from the Protein Data Bank (PDB 2R8Q) and prepared using the Protein Preparation Wizard
tool (39) implemented on Maestro (40). Automated docking was used to assess the appropriate binding
orientations and conformations of the ligand. A Lamarckian genetic algorithm (41) method implemented
in the program AutoDock 4.2 (42) was employed. For docking calculations, Gasteiger charges were
added, rotatable bonds were set by the use of AutoDock tools (ADT), and all torsions were allowed to
rotate for the ligand. In all cases, we used grid maps with a grid box size of 60-by-60-by-60 Å3 points and
a grid-point spacing of 0.375 Å, using Gln887 as the centroid of the grid. The docking protocol consisted
of 100 independent Genetic Algorithm (GA) runs, a population size of 150, and a maximum of 250,000
evaluations, while the other parameters were defaults. The ﬁnal best-docked clusters, within the default
2.0-Å root mean square deviation (RMSD), according to the binding energies and relative population data
provided by Autodock, were analyzed by visual inspection. In both complexes, two main clusters were
found in terms of energy and were also the most highly populated ones, and those clusters were
therefore selected for further analysis (Fig. S3 and S4).
Molecular dynamics (MD) studies. An Optimized Potentials for Liquid Simulations-2005 (OPLS2005)
(43) force ﬁeld was used as the force ﬁeld in a Desmond molecular dynamics system (44) to study the
behavior of the ligand-target complex. The protein-ligand complexes obtained from the AutoDock
docking protocol were prepared using the Desmond setup wizard. For ligand 35, QMESP charges were
calculated using Jaguar software (45), carrying out a geometry optimization with the basis set CC-
PVTZ. Charges were added to the best docking output pose for further use. The system was solvated
in a triclinical periodic box of simple point-charge (SPC) water and then neutralized using an appropriate
number of counter ions. Also, a physiological NaCl concentration of 0.15 M was added in the system
builder. The method selected for MD was NPT (Noose-Hover chain thermostat [at 300 K; Martyna-Tobias-
Klein barostat at 10.13255 pascals]); no constraints were applied in the MD protocol. Energy minimization
of the prepared system was done using up to a maximum of 10 steps and the steepest-descent method
or until a gradient threshold (25 kcal/mol/Å) was reached. The default Desmond protocol was used to
equilibrate the system. Further MD simulations were carried out on these equilibrated systems for a time
period of 20 ns. The quality of MD simulations was assessed using the Simulation Quality Analysis tools
and analyzed by the Simulation Event Analysis tool, and ligand-receptor interactions were identiﬁed
using the Simulation Interaction Diagram tool. Energy ﬂuctuations, RMSD, and root-mean-square ﬂuc-
tuations (RMSF) of the complexes in each trajectory were analyzed with respect to simulation time.
Visualization and analysis of the dynamics trajectories were performed using both Visual Molecular
Dynamics (VMD) (46) and Desmond Maestro simulation analysis tools.
cAMP determination in Leishmania promastigotes. Incubations of promastigotes were performed
in 24-well plates with either 2 or 5 the IC50 of compound 35 for 3 h and were initiated by adding 15
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l of each compound, at a concentration of 100 in 100% DMSO, to reach a level of 1.5 ml of culture.
A 1.5-ml control culture received 15 l of solvent (100% DMSO). After 3 h, a sample containing 5  106
cells was taken from each well and centrifuged at 4,500  g for 10 min at 4°C and the supernatant was
carefully removed. For quantiﬁcation of the intracellular cAMP, the cell pellet was immediately resus-
pended in 100 l 0.1 M HCl (by repeated up-and-down pipetting) and incubated on ice for 20 min in
order to obtain complete cell lysis. The suspensions were then centrifuged at 10,300  g in a
microcentrifuge for 10 min at 4°C, and the supernatant (lysate) was transferred to a fresh microcentrifuge
tube that was stored at 20°C. The experiment was performed three times independently, and all
samples were assayed in duplicate using a direct cyclic AMP enzyme immunoassay kit (Assay Designs)
according to the manufacturer’s instructions.
Efﬁcacy potential in the L. infantum BALB/c mouse model. Female BALB/c mice (body weight
[BW], approximately 20 g) were purchased from a commercial source (Janvier Labs, France) and kept in
quarantine for at least 5 days before the experiment was started. Food and drinking water were available
for laboratory rodents ad libitum. The mice were randomly allocated to experimental units of 6
animals/group based on live BW at the start of the experiment (day 0 day of infection). Spleen-derived
L. infantum amastigoteswere puriﬁed using two centrifugation steps and diluted for preparation of an
infection inoculum containing 2 107 amastigotes/100 l phosphate-buffered saline (PBS). The infection
inoculum was administered by slow intravenous injection in the tail vein. The test compounds (com-
pounds 35 and 45) were formulated in polyethylene glycol (PEG 400) at 25 mg/ml for a planned dosing
level of 50 l/25 g. Miltefosine was formulated in water at 10 mg/ml for a planned dosing level of 100
l/25 g. The 5-day oral treatment started at day 7 postinfection and involved 4 groups: group 1 (G1; PEG
400 vehicle b.i.d.), G2 (miltefosine at 40 mg/kg of body weight s.i.d.), G3 (compound 45 at 50 mg/kg
b.i.d.), and G4 (compound 35 at 50 mg/kg b.i.d.) (50 l/25 g). All animals were weighed twice weekly to
monitor the general health status (severity of infection and toxicity of medication). Amastigote burdens
in the liver and spleen target organs were determined on days 16 and 17 of the experiment. Organs of
individual animals were weighed, and impression smears were subjected to Giemsa staining for micro-
scopic evaluation of the total amastigote burden (the mean number of amastigotes per cell  number
of cells counted [minimum of 500 nuclei]). Percent reduction compared to the burdens in the vehicle-
treated infected control animals was used as a measure of drug activity.
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